Search clinical trials for: Adavosertib

Total 62 results

AstraZeneca
Parexel

Terminated

Human Absorption, Distribution, Metabolism, and Excretion Study of [14C]Adavosertib (ADME)

Advanced Solid Tumors

United Kingdom
Merck Sharp & Dohme LLC

Terminated

A Dose Escalation Study of Adavosertib(MK1775) in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005

Solid Tumors
Merck Sharp & Dohme LLC

Terminated

A Study of Adavosertib (MK-1775) in Combination With Topotecan/Cisplatin in Participants With Cervical Cancer (MK-1775-008)

Cervical Cancer
AstraZeneca

Completed

Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours

Advanced Solid Tumours

Japan
Merck Sharp & Dohme LLC

Completed

A Dose Escalation Study of Adavosertib (MK-1775) in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001)

Solid Tumors
AstraZeneca

Completed

Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.

Ovarian Cancer | Locally Advanced Solid Tumours | Metastatic Solid Tumours

United States
AstraZeneca
Parexel

Terminated

A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours

Advanced Solid Tumours

United Kingdom, United States
Merck Sharp & Dohme LLC

Completed

A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)

Ovarian Cancer
AstraZeneca
Parexel

Completed

A Study of Adavosertib as Treatment for Uterine Serous Carcinoma (ADAGIO)

Uterine Serous Carcinoma

United States, Italy, Spain, France, Canada
Samsung Medical Center

Terminated

Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 Mutation

Small Cell Lung Cancer

Korea, Republic of
Samsung Medical Center

Completed

Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients

Small Cell Lung Cancer

Korea, Republic of
Dana-Farber Cancer Institute
AstraZeneca

Active, not recruiting

AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma

Uterine Cancer

United States
AstraZeneca

Completed

Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours

Ovarian Cancer, TNBC, SCLC, Other Solid Tumours

United States, Canada
National Cancer Institute (NCI)

Completed

AZD1775 for Advanced Solid Tumors

Solid Tumors

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
St. Joseph's Hospital and Medical Center, Phoenix
Barbara Ann Karmanos Cancer Institute; American Society of Clinical Oncology; Translational Genomics Research Institute and other collaborators

Completed

A Phase 0 Study of AZD1775 in Recurrent GBM Patients

Glioblastoma | GBM

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2

Clear Cell Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Locally Advanced Malignant Solid Neoplasm | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Locally Advanced Clear Cell Renal Cell Carcinoma

United States
National Cancer Institute (NCI)

Completed

AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm

United States
University of Birmingham
AstraZeneca; Cancer Research UK

Completed

WEE1 Inhibitor With Cisplatin and Radiotherapy: A Trial in Head and Neck Cancer (WISTERIA)

Larynx Cancer | Oral Cavity Squamous Cell Carcinoma | Hypopharynx Squamous Cell Carcinoma

United Kingdom
Dana-Farber Cancer Institute
AstraZeneca

Completed

CISPLATIN + AZD-1775 In Breast Cancer

Triple-negative Metastatic Breast Cancer

United States
The Netherlands Cancer Institute
Merck Sharp & Dohme LLC

Completed

Study With Wee-1 Inhibitor AZD1775 (MK-1775) and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer (M10MKO)

Epithelial Ovarian Cancer

Netherlands
AstraZeneca

Completed

AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors

Refractory Solid Tumours | Relapsed Small Cell Lung Cancer (SCLC)

United States, Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Primary Peritoneal High Grade Serous Adenocarcinoma | Stage III Fallopian Tube Cancer AJCC v7 | Stage III Ovarian Cancer AJCC v6 and v7 | Stage III Primary Peritoneal Cancer AJCC v7 | Stage IIIA Fallopian Tube Cancer AJCC v7 | Stage IIIA Ovarian Cancer AJCC v6 and v7 | Stage IIIA Primary Peritoneal... and other conditions

United States
AstraZeneca

Active, not recruiting

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

Metastatic Triple Negative Breast Cancer

United States, Belgium, Italy, Spain, United Kingdom, Canada, Czechia, Poland, France, Korea, Republic of, Germany, Taiwan, Portugal, Netherlands, Ireland
NYU Langone Health

Terminated

AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myelofibroses

United States
NYU Langone Health
AstraZeneca

Completed

Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

United States
Joseph Paul Eder
Dana-Farber Cancer Institute; The Cleveland Clinic; Vanderbilt-Ingram Cancer...

Terminated

OLAParib COmbinations (OLAPCO)

Cancer

United States
Samsung Medical Center

Completed

Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy

Advanced Gastric Adenocarcinoma

Korea, Republic of
UNC Lineberger Comprehensive Cancer Center
AstraZeneca

Completed

Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC

Carcinoma, Squamous Cell of Head and Neck

United States
AstraZeneca

Active, not recruiting

Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours

Advanced Solid Tumours

United States
National Cancer Institute (NCI)

Terminated

Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia

Acute Myeloid Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1... and other conditions

United States
AstraZeneca
Quintiles, Inc.

Completed

AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies

Solid Tumors

United States, France, United Kingdom, Netherlands
AstraZeneca

Terminated

A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer

Previously Treated Non Small Cell Lung Cancer

United States
AstraZeneca

Active, not recruiting

Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (BISCAY)

Muscle Invasive Bladder Cancer

Spain, United States, Canada, France, United Kingdom
H. Lee Moffitt Cancer Center and Research Institute

Completed

AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer

Lung Cancer

United States
James Cleary, MD, PhD
AstraZeneca; Stand Up To Cancer; Lustgarten Foundation

Withdrawn

Adavosertib and Gemcitabine in Advanced Pancreatic

Pancreatic Cancer
Canadian Cancer Trials Group
Canadian Cancer Clinical Trials Network; BC Cancer Foundation

Active, not recruiting

Prostate Cancer Biomarker Enrichment and Treatment Selection

Prostate Cancer

Canada
Case Comprehensive Cancer Center

Not yet recruiting

ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck

Head and Neck Squamous Cell Carcinoma | Recurrent Squamous Cell Carcinoma of the Head and Neck | Metastatic Squamous Cell Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Metastatic Malignant Neoplasm in the Brain and other conditions

United States
University of Michigan Rogel Cancer Center

Completed

Dose Escalation Trial of AZD1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas

Adenocarcinoma of the Pancreas

United States
AstraZeneca
Quintiles, Inc.

Completed

Phase I Study to Assess the Effect of Food on AZD1775 Pharmacokinetics in Patients With Advanced Solid Tumours

Solid Tumours

France, United Kingdom, Netherlands
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
AstraZeneca

Completed

A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma

Spain, Poland, Hungary, Ukraine, Germany
AstraZeneca

Terminated

Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer

Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer

United States
AstraZeneca

Completed

Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours

Advanced Solid Tumours

Korea, Republic of, Australia, Japan
National Cancer Institute (NCI)

Completed

Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas

Glioblastoma | Gliosarcoma | Anaplastic Oligoastrocytoma | Anaplastic Astrocytoma | Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Ovarian Undifferentiated Carcinoma | Ovarian... and other conditions

United States, Canada, Singapore
AstraZeneca

Completed

Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation

United States, Canada, Netherlands
National Cancer Institute (NCI)

Completed

Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Refractory Malignant Solid Neoplasm | Pineoblastoma | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent Rhabdomyosarcoma | Refractory Medulloblastoma | Refractory Neuroblastoma | Refractory Rhabdomyosarcoma | Central Nervous System Embryonal Tumor With... and other conditions

United States, Canada

Search clinical trials for: Adavosertib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations